Nvidia Corp vs Zoetis Inc — how do they compare? Nvidia Corp trades at $222.85 (market cap $5.45T), while Zoetis Inc trades at $73.95 (market cap $30.40B). The key difference: Nvidia Corp is far larger — about 179.3× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.88%). Which is the better fit depends on your goals.
| NVDA | ZTS | |
|---|---|---|
Market Cap | $5.45T | $30.40B |
Sector | Technology | Health |
52-Week High | $235.75 | $150.61 |
52-Week Low | $165.17 | $71.91 |
Enterprise Value | $5.43T | $37.96B |
Dividend Yield | 0.44% | 2.88% |
Signals from Pluang's Aura AI — not financial advice
NVIDIA (NVDA) trades at $225.73, down 2.01% over the past day, amid a broader tech sell-off. The stock maintains a bullish technical signal with strong moving average support, while oscillators are neutral. Fundamentally, the company reported robust revenue of $130.50B in 2025, with net income surging to $72.88B, reflecting a 55.84% profit margin. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.22 surpassing the $2.09 estimate. Analyst sentiment remains overwhelmingly positive, with a consensus price target of $344.10 implying significant upside.
Outlook: NVDA's leadership in AI chips and accelerating revenue growth present a compelling investment case, though risks include heightened competition and potential market saturation. The stock's current valuation metrics, such as a P/E of 28.54, appear reasonable given its growth trajectory. Institutional ownership trends and strong cash flow generation support long-term bullish sentiment, but investors should monitor execution risks and macroeconomic headwinds.
Zoetis (ZTS) trades at $73.60, down 2.92% amid bearish technical signals and mixed earnings. The stock faces pressure from weakening U.S. companion animal sales and competitive headwinds, though profitability remains strong with 71.67% gross margins and 27.69% net income margin. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a guidance cut. Analyst consensus is divided with 45% Buy ratings and a $93.40 price target, suggesting 27% upside from current levels.
The outlook balances valuation appeal (P/E of 12) against near-term operational challenges. Investment opportunity lies in market dominance and robust cash flow generation, while risks include sustained pet health demand softness and competitive pricing pressure. The stock trades near support at $73, with institutional sentiment mixed amid recent portfolio adjustments.
Trailing returns across standard periods
Latest headlines on both assets
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →